Novartis hires Harvard star to plug gaps in cancer drug arsenal

Reuters/Arnd Wiegmann. ZURICH Pharmaceuticals giant Novartis is pinning its hopes on a 43-year-old Harvard cancer research star to help fill gaps in its immuno-oncology arsenal after "missing the boat" on some promising therapies.